IPHA: Innate Pharma, S.A. Net earnings per share (EPS TTM)

Innate Pharma (IPHA) - corporate logo

The development of unique molecules to activate immunity against tumors supports an upward trend for Innate Pharma S.A. (IPHA), where the net income per share over the last 12 months recorded a fresh value of -0.59. Stable management relies on large-scale R&D alliances with pharma behemoths, while optimized international antibody logistics minimize customs risks, ensuring high profitability across the entire supply chain.

IPHA Innate Pharma S.A. Net earnings per share for the last 12 months (07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for Innate Pharma SA (IPHA)

- share price and expert price forecast:
Stock Quotes Innate Pharma S.A.|IPHA - Fair Value Consensus
- market capitalization information:
Market Capitalization Innate Pharma S.A.|IPHA - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Innate Pharma|IPHA - Company Net Assets|Market Value to Book Value Ratio innate-pharma.com|IPHA - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Debt to Capital|Short-Term Debt to Equity Innate Pharma, S.A.|IPHA - Company Aggregate Debt|Debt to Book Capitalization Ratio Innate Pharma S.A.|IPHA - Long-Term Debt|Company Current Liabilities Innate Pharma|Quick Liquidity Indicator innate-pharma.com
- earnings and multiples data:
IPHA - Profit After Payment of Taxes|Projected Future Earnings Innate Pharma S.A.|IPHA - Company Value to Net Income|Forward P/E Multiple Innate Pharma|IPHA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Innate Pharma S.A.|IPHA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Innate Pharma|IPHA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months innate-pharma.com|IPHA - Earnings per share trend in current year|Expected earnings per share growth for next year Innate Pharma S.A.
Fundamental valuation:IPHA - Innate Pharma S.A.
Flagship merchandise of Innate Pharma, S.A.

For the French developer of immuno-oncology drugs, whose operations are protected by international humanitarian status, the rolling 12-month EPS serves as an indicator of the efficiency of R&D cycle monetization. This metric is calculated as the ratio of total net income to the number of shares outstanding, allowing investors to assess the real return on each share and the sustainability of the Innate Pharma S.A. (IPHA) business model amid global clinical trials.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma)|Earnings per share for the trailing year ALXO|Cue Biopharma, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months PDS Biotechnology|sonnetbio.com (SONN) - Earnings per share for the last twelve months|MAIA Bio - Earnings per share for the trailing year|LIMN (Liminatus Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Lava Tx|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|Theriva Biologics, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Gritstone bio, Inc. GRTS|Kineta (KA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NEXI|Earnings per share for the last twelve months Turnstone Biologics Corp|Earnings per share for the last 12 months VCNX (Vaccinex Inc)|Net earnings per share (EPS TTM) HARP